Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06561048 · ClinicalTrials.gov registry record · Phase 3
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
A Phase 3 study of Angioimmunoblastic T-cell Lymphoma and Lymphoma, T-Cell, sponsored by Corvus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 17
- Study locations
NCT06561048 is a Phase 3 study of Angioimmunoblastic T-cell Lymphoma and Lymphoma, T-Cell that is actively recruiting participants, run by Corvus Pharmaceuticals. The registered enrollment target is 150 participants, above the 63-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (138% higher). The trial reports 17 study locations across 15 states.
The verdict
NCT06561048, a Phase 3 study of Angioimmunoblastic T-cell Lymphoma and Lymphoma, T-Cell, is actively recruiting participants, sponsored by Corvus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 17
- Study locations
Study Summary
A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).
Conditions Studied
Interventions
- DRUG Belinostat
- DRUG Pralatrexate
- DRUG Soquelitinib
Study Locations (17)
California
- City of Hope National Medical Center - Duarte
- University of California, Irvine - Irvine
- University of California San Francisco - San Francisco
Connecticut
- Yale University - New Haven
Georgia
- Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Maryland
- University of Maryland Medical Center - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
Missouri
- Washington University in St. Louis - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-10-02 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06561048
The ClinicalTrials.gov registry entry for NCT06561048 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 63-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (138% higher). The listed sponsor is Corvus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Angioimmunoblastic T-cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Belinostat is the first listed.
NCT06561048 reports 17 study locations spanning 15 distinct geographic areas - top geographies include California, Connecticut, Georgia.
Frequently Asked Questions
What is clinical trial NCT06561048 about?
NCT06561048 is a clinical study titled "Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma". A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper ...
What is the current status of trial NCT06561048?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-10-02. Estimated completion is 2028-07.
What conditions does trial NCT06561048 study?
This clinical trial studies the following conditions: Angioimmunoblastic T-cell Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Follicular T-Cell Lymphoma.
What interventions are being tested in trial NCT06561048?
The interventions under investigation include: Belinostat (DRUG), Pralatrexate (DRUG), Soquelitinib (DRUG).
Who is sponsoring clinical trial NCT06561048?
This trial is sponsored by Corvus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06561048 being conducted?
This trial has 17 study locations across California, Connecticut, Georgia, Iowa, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angioimmunoblastic T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.